RXi Shortens Strands for Effective Drug Delivery
Geert Cauwenbergh, President & CEO for RXi Pharmaceuticals, shares the company’s role in making RNAI relevant to ophthalmology. Highlighting their research surrounding the delivery of drug to the eye, Geert expands on their unique modification to create shorter passenger strands to accompany the longer guide strand to facilitate delivery to the eye effectively.
Presenter:
Geert Cauwenbergh
Dr. Cauwenbergh is President and CEO of RXi Pharmaceuticals, Corp. Prior to this role, he served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development.